Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production. Itolizumab can be used to study conditions such as psoriasis, rheumatoid arthritis (RA), and COVID-19 disease.

Inhibiting T cell proliferation, Itolizumab is effective at a concentration of 100 μg/mL[1].
In PBMCs, Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances the acquisition of the Th1 phenotype[1].
During overnight culture of PBMCs, Itolizumab at 40 μg/mL reduces CD26hiCD161+ CD8+ T cells[2].
In PBMCs stimulated in Th17 polarizing conditions, Itolizumab at 40 μg/mL for 3-12 days reduces the expression of IL-17 and IFN-γ[3].

In a humanized xenograft mouse model of Graft Vs Host Disease (GVHD), Itolizumab demonstrates therapeutic efficacy when administered intraperitoneally at doses of 60 μg or 300 μg daily[4].

Human

Immobilized Human CD6 Protein (His) at 2 μg/mL (30 μL/well) can bind Itolizumab. The EC50 is 2.809 ng/mL.

Monoclonal

Unconjugated